{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:34:47Z","timestamp":1791462887156,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Addictive Behaviors"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.addbeh.2021.107113","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T11:53:29Z","timestamp":1630929209000},"page":"107113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race\/ethnicity, and gender in the United States"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6644-4841","authenticated-orcid":false,"given":"Martin","family":"Hochheimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Jay","family":"Unick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addbeh.2021.107113_b0005","unstructured":"Substance Abuse and Mental Health Services Administration. (2019). SSDUH Detailed Tables 2020."},{"key":"10.1016\/j.addbeh.2021.107113_b0010","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1517\/14656560903037168","article-title":"Opioid dependence treatment: Options in pharmacotherapy","volume":"10","author":"Stotts","year":"2009","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.addbeh.2021.107113_b0015","series-title":"Medications for opioid use disorder save lives","author":"Mancher","year":"2019"},{"key":"10.1016\/j.addbeh.2021.107113_b0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of opioid-use disorders","volume":"375","author":"Longo","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.addbeh.2021.107113_b0025","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ (Clinical Research Ed)"},{"key":"10.1016\/j.addbeh.2021.107113_b0030","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3109\/16066359.2010.530715","article-title":"Perceived barriers to identity transformation for people who are prescribed methadone","volume":"19","author":"Doukas","year":"2011","journal-title":"Addiction Research & Theory"},{"key":"10.1016\/j.addbeh.2021.107113_b0035","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.addbeh.2021.107113_b0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2018.08.007","article-title":"Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years","volume":"836","author":"Blanco-Gand\u00eda","year":"2018","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.addbeh.2021.107113_b0045","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.drugalcdep.2018.08.019","article-title":"Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder","volume":"192","author":"Carroll","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.addbeh.2021.107113_b0050","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cpr.2017.10.012","article-title":"Sex and gender differences in substance use disorders","volume":"66","author":"McHugh","year":"2018","journal-title":"Clinical Psychology Review"},{"key":"10.1016\/j.addbeh.2021.107113_b0055","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/1552-6909.12306","article-title":"Experiences of mothers of infants with neonatal abstinence syndrome in the neonatal intensive care unit","volume":"43","author":"Cleveland","year":"2014","journal-title":"Journal of Obstetric, Gynecologic & Neonatal Nursing"},{"key":"10.1016\/j.addbeh.2021.107113_b0060","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/jnr.23963","article-title":"Sex differences, gender and addiction","volume":"95","author":"Becker","year":"2017","journal-title":"Journal of Neuroscience Research"},{"key":"10.1016\/j.addbeh.2021.107113_b0065","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/10826084.2017.1334070","article-title":"Racial\/ethnic differences in prevalence trends for heroin use and non-medical use of prescription opioids among entrants to opioid treatment programs, 2005\u20132016","volume":"53","author":"Pouget","year":"2018","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.addbeh.2021.107113_b0070","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/EDE.0000000000000858","article-title":"Trends in Black and White opioid mortality in the United States, 1979\u20132015","volume":"29","author":"Alexander","year":"2018","journal-title":"Epidemiology (Cambridge, Mass)"},{"key":"10.1016\/j.addbeh.2021.107113_b0075","doi-asserted-by":"crossref","unstructured":"Furr-Holden D., Milam A. J., Wang L., & Sadler R. (2021). African Americans now outpace whites in opioid-involved overdose deaths: a comparison of temporal trends from 1999 to 2018, Addiction 2020: n\/a.","DOI":"10.1111\/add.15233"},{"key":"10.1016\/j.addbeh.2021.107113_b0080","doi-asserted-by":"crossref","unstructured":"Proctor S. L., Copeland A. L., Kopak A. M., Hoffmann N. G., Herschman P. L., & Polukhina N. (2015). Predictors of patient retention in methadone maintenance treatment, Psychology of Addictive Behaviors. 29: 906\u2013917.","DOI":"10.1037\/adb0000090"},{"issue":"1","key":"10.1016\/j.addbeh.2021.107113_b0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1521-0391.2013.00317.x","article-title":"Predictors of dropout from psychosocial treatment in opioid-dependent outpatients","volume":"22","author":"McHugh","year":"2013","journal-title":"The American Journal on Addictions"},{"issue":"6","key":"10.1016\/j.addbeh.2021.107113_b0090","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/ajad.12553","article-title":"Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration","volume":"26","author":"Manhapra","year":"2017","journal-title":"The American journal on addictions"},{"key":"10.1016\/j.addbeh.2021.107113_b0095","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/1073110518782949","article-title":"The opioid crisis in Black communities","volume":"46","author":"James","year":"2018","journal-title":"The Journal of Law, Medicine & Ethics"},{"key":"10.1016\/j.addbeh.2021.107113_b0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jsat.2011.12.006","article-title":"Superior methadone treatment outcome in Hmong compared with non-Hmong patients","volume":"43","author":"Bart","year":"2012","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.addbeh.2021.107113_b0105","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10550887.2012.694598","article-title":"Maintenance medication for opiate addiction: The foundation of recovery","volume":"31","author":"Bart","year":"2012","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.addbeh.2021.107113_b0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.drugalcdep.2018.08.024","article-title":"Three-year retention in methadone opioid agonist treatment: A survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets","volume":"193","author":"Amiri","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.addbeh.2021.107113_b0115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: A systematic review AU \u2013 Timko, Christine","volume":"35","author":"Timko","year":"2016","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.addbeh.2021.107113_b0120","series-title":"Stata statistical software: Release 16","author":"StataCorp","year":"2019"},{"key":"10.1016\/j.addbeh.2021.107113_b0125","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3109\/10826087609058818","article-title":"Retention of patients in the New York City Methadone Maintenance Treatment Program","volume":"11","author":"Newman","year":"1976","journal-title":"International Journal of the Addictions"},{"key":"10.1016\/j.addbeh.2021.107113_b0130","series-title":"Practical meta-analysis","author":"Lipsey","year":"2001"},{"key":"10.1016\/j.addbeh.2021.107113_b0135","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1080\/01490400701881366","article-title":"Understanding meta-analysis: A review of the methodological literature","volume":"30","author":"Shelby","year":"2008","journal-title":"Leisure Sciences"},{"key":"10.1016\/j.addbeh.2021.107113_b0140","first-page":"563","article-title":"Outcomes of methadone treatment of 300 innercity addicts","volume":"89","author":"Cleveland","year":"1974","journal-title":"Health Services Reports"},{"key":"10.1016\/j.addbeh.2021.107113_b0145","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jsat.2009.05.003","article-title":"Buprenorphine maintenance treatment in a primary care setting: Outcomes at 1 year","volume":"37","author":"Soeffing","year":"2009","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.addbeh.2021.107113_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2018.11.002","article-title":"A retrospective analysis of treatment and retention outcomes of pregnant and\/or parenting women with opioid use disorder","volume":"97","author":"Lopian","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.addbeh.2021.107113_b0155","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jama.281.11.1000","article-title":"Moderate- vs high-dose methadone in the treatment of opioid dependence: A randomized trial, JAMA","volume":"281","author":"Strain","year":"1999","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.addbeh.2021.107113_b0160","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jsat.2009.08.001","article-title":"Home- versus office-based buprenorphine inductions for opioid-dependent patients","volume":"38","author":"Sohler","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.addbeh.2021.107113_b0165","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jsat.2015.07.005","article-title":"A phase 4, pilot, open-label study of VIVITROL(R) (extended-release naltrexone XR-NTX) for prisoners","volume":"59","author":"Gordon","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.addbeh.2021.107113_b0170","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in Office Based Opioid Treatment with buprenorphine","volume":"74","author":"Weinstein","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.addbeh.2021.107113_b0175","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/10550887.2012.759872","article-title":"A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction","volume":"32","author":"Neumann","year":"2013","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.addbeh.2021.107113_b0180","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1525-1497.2005.0228.x","article-title":"Buprenorphine retention in primary care","volume":"20","author":"Stein","year":"2005","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.addbeh.2021.107113_b0185","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/02791072.1996.10472487","article-title":"Retention in methadone maintenance treatment programs, Connecticut and Massachusetts, 1990\u20131993","volume":"28","author":"MacGowan","year":"1996","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.addbeh.2021.107113_b0190","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2012.12.010","article-title":"Patient characteristics associated with buprenorphine\/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study","volume":"131","author":"Dreifuss","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.addbeh.2021.107113_b0195","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.addbeh.2012.04.011","article-title":"Predictors of attrition with buprenorphine\/naloxone treatment in opioid dependent youth","volume":"37","author":"Warden","year":"2012","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.addbeh.2021.107113_b0200","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/ajad.12414","article-title":"Predictors of early dropout in outpatient buprenorphine\/naloxone treatment","volume":"25","author":"Marcovitz","year":"2016","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.addbeh.2021.107113_b0205","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","article-title":"Collaborative care of opioid-addicted patients in primary care using buprenorphine: Five-year experience","volume":"171","author":"Alford","year":"2011","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.addbeh.2021.107113_b0210","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1300\/J126v02n01_09","article-title":"Costs and benefits of methadone treatment in DATOS \u2013 Part 2: Gender differences for discharged and continuing patients","volume":"2","author":"Flynn","year":"2002","journal-title":"Journal of Maintenance in the Addictions"},{"key":"10.1016\/j.addbeh.2021.107113_b0215","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1080\/00952990.2018.1461877","article-title":"Treatment outcomes among a cohort of African American buprenorphine patients: Follow-up at 12 months","volume":"44","author":"Monico","year":"2018","journal-title":"American Journal of Drug & Alcohol Abuse"},{"key":"10.1016\/j.addbeh.2021.107113_b0220","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.puhe.2015.10.027","article-title":"The development and validation of a meta-tool for quality appraisal of public health evidence: Meta Quality Appraisal Tool (MetaQAT)","volume":"136","author":"Rosella","year":"2016","journal-title":"Public Health"},{"key":"10.1016\/j.addbeh.2021.107113_b0225","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.drugalcdep.2019.02.007","article-title":"A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions","volume":"197","author":"Ling","year":"2019","journal-title":"Drug & Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.addbeh.2021.107113_b0230","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1377\/hlthaff.2011.0983","article-title":"Blacks And Hispanics are less likely than Whites to complete addiction treatment, largely due to socioeconomic factors","volume":"32","author":"Saloner","year":"2013","journal-title":"Health Affairs"},{"key":"10.1016\/j.addbeh.2021.107113_b0235","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/00952991003736389","article-title":"Predictors of attrition from a national sample of methadone maintenance patients","volume":"36","author":"Mancino","year":"2010","journal-title":"American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.addbeh.2021.107113_b0240","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamapediatrics.2017.0745","article-title":"Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001\u20132014","volume":"171","author":"Hadland","year":"2017","journal-title":"JAMA Pediatrics"},{"key":"10.1016\/j.addbeh.2021.107113_b0245","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11414-013-9341-3","article-title":"Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City","volume":"40","author":"Hansen","year":"2013","journal-title":"The Journal of Behavioral Health Services & Research"},{"key":"10.1016\/j.addbeh.2021.107113_b0250","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.drugalcdep.2015.12.035","article-title":"Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration","volume":"160","author":"Manhapra","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.addbeh.2021.107113_b0255","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.drugalcdep.2017.08.019","article-title":"The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use","volume":"180","author":"Huhn","year":"2017","journal-title":"Drug & Alcohol Dependence"},{"key":"10.1016\/j.addbeh.2021.107113_b0260","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2016.02.009","article-title":"Patients' beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification","volume":"66","author":"Uebelacker","year":"2016","journal-title":"Journal of Substance Abuse Treatment"}],"container-title":["Addictive Behaviors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460321002987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460321002987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T18:48:28Z","timestamp":1759690108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306460321002987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":52,"alternative-id":["S0306460321002987"],"URL":"https:\/\/doi.org\/10.1016\/j.addbeh.2021.107113","relation":{},"ISSN":["0306-4603"],"issn-type":[{"value":"0306-4603","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race\/ethnicity, and gender in the United States","name":"articletitle","label":"Article Title"},{"value":"Addictive Behaviors","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addbeh.2021.107113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107113"}}